Navigation Links
Phase 3 trial finds no benefit from atrasentan added to chemo for advanced prostate cancer
Date:4/21/2011

ANN ARBOR, MICH. -- A Data and Safety Monitoring Committee (DSMC) has determined that patients in a phase III clinical trial given atrasentan in addition to a standard chemotherapy regimen for advanced prostate cancer did not have longer survival or longer progression-free survival than patients on the same chemotherapy regimen who got a placebo rather than atrasentan.

Almost 1,000 patients who had advanced, hormone-refractory prostate cancer were given up to 36 weeks of chemotherapy with docetaxel and prednisone. These patients were randomized so that one half got an additional pill with a dose of atrasentan while the other half got a placebo pill. Patients who completed their chemotherapy and showed no progression of the disease were given the option of continuing the additional blinded pill (atrasentan or placebo).

The study's DSMC evaluated a planned interim analysis of trial data and determined the evidence indicating no benefit from the drug was strong enough to close the study early rather than waiting another 18 months as was originally planned. The DSMC did not find evidence that the drug was harming patients.

New patient enrollment to the study stopped in April 2010 and few patients continue to take the study pill. Patients still taking study medication should speak to their doctor about stopping safely and what to do with their remaining pills. Treatment assignment is being unblinded, so patients can learn from their study doctor whether they took atrasentan or a placebo.

The study ("S0421: Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer") was supported by the National Cancer Institute (NCI) and was conducted by SWOG (formerly the Southwest Oncology Group) with the participation of several other NCI cooperative groups.

Atrasentan for the trial was provided under an agreement with Abbott Laboratories and was distributed by the Department of Veterans Affairs Cooperative Studies Program Clinical Research Pharmacy Coordinating Center.


'/>"/>

Contact: Frank DeSanto
fdesanto@umich.edu
734-998-0114
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. NHGRI charts course for the next phase of genomics research
2. Phase III efficacy data on bevacizumab plus chemotherapy in early breast cancer to be presented
3. Euthymics presents phase II data for EB-1010 in major depression at ACNP annual meeting
4. Phase I trial indicates ponatinib may thwart most resistant CML
5. Assessing positive outcomes of phase III trials
6. Professor Zvi Ram presents phase III recurrent glioblastoma survival and quality of life data from the first pivotal study of the NovoTTF-100A at 15th Annual Society for Neuro-Oncology Scientific Meeting
7. Nutrition rating enhancing front-of-package nutrition rating systems and symbols: Phase 1
8. New Phase II study shows first-line promise of lung cancer drug PF-299
9. Pazopanib shows promise in Phase II trial for relapsed/refractory urothelial cancer
10. Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors
11. Front-of-package symbols and systems: IOM phase 1 report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2020)... Va. (PRWEB) , ... May 21, 2020 , ... A ... and Medicine Group, details over 90 companies involved in the point of care ... many hospital facilities for preliminary testing, COVID-19 has made point-of-care more important than in ...
(Date:5/17/2020)... (PRWEB) , ... May 18, 2020 , ... ... stem cell therapy program at its Tijuana regenerative clinic. There are two program ... effective and safe cell counts. , While it is unclear exactly what causes ...
(Date:5/16/2020)... ... May 15, 2020 , ... On May 21, T1V will host a webinar featuring ... of USC, and a contributor to CBS news, as we address COVID-19 and the impact ... most parts of the country since March, many questions are left unanswered as we look ...
(Date:5/16/2020)... ... 16, 2020 , ... Dr. Tomasz Biernacki states that “If bunion ... from developing. This can keep the foot from being unable to fit into good ... the people who develop flat feet and bunion formation can have further ...
(Date:5/15/2020)... ... ... Collagen has taken the areas of beauty and anti-aging by storm, up by ... Nutritional Outlook ‘Ingredients to Watch’ US forecast. Collagen ingredients have matured in front of ... low-impact products of the past to the clinically-studied, low-molecular weight hydrolysates of today. , ...
Breaking Medicine News(10 mins):
(Date:5/30/2020)... ... May 29, 2020 , ... United ... to the U.S. announcement that it will terminate its relationship with the World ... it plans to terminate its relationship with the World Health Organization. Any move ...
(Date:5/30/2020)... ... May 30, 2020 , ... ... a host of new issues related to COVID-19. Recently, Wellness Expert Jamie Hess ... expectant moms support their pregnancy and postpartum. , A video accompanying this ...
(Date:5/28/2020)... ... May 28, 2020 , ... May is Talking is Power Month, a national ... care about them. The focus of Power to Decide’s #TalkingIsPower campaign reminds parents, trusted ... Power to Decide’s Mackenzie Piper, MPH, CHES, provides five strategies parents, trusted adults and ...
Breaking Medicine Technology: